Type 2 Diabetes: Incremental Medical Care Costs During the 8 Years Preceding Diagnosis. Diabetes Care 23: , 2000
|
|
- Rosanna Bishop
- 5 years ago
- Views:
Transcription
1 Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Type 2 Diabetes: Incremental Medical Care Costs During the 8 Years Preceding Diagnosis GREGORY A. NICHOLS, PHD HARRY S. GLAUBER, MD JONATHAN B. BROWN, PHD, MPP OBJECTIVE To describe and analyze medical care costs for the 8 years preceding a diagnosis of type 2 diabetes. RESEARCH DESIGN AND METHODS From electronic records of a large groupmodel health maintenance organization (HMO), we ascertained the medical care costs preceding diagnosis for all members with type 2 diabetes who were newly diagnosed between 1988 and To isolate incremental costs (costs caused by the future diagnosis of diabetes), we subtracted the costs of individually age- and sex-matched HMO members without impending diabetes from the costs of members who were destined to receive this diagnosis. We also compared these prediagnosis costs with the first 3 years of postdiagnosis costs. RESULTS An economic burden from impending diabetes is apparent for at least 8 years before diagnosis, beginning with costs for outpatient and pharmacy services. Diabetes-associated incremental costs (costs of type 2 diabetic patients minus matched costs of nondiabetic patients) averaged $1,205 per type 2 diabetic patient per year during the first eight prediagnostic years, including $1,913 each year for the 3 years preceding diagnosis. In the year immediately preceding diagnosis, incremental costs were equivalent to those observed in the second and third years after diagnosis. CONCLUSIONS Incremental costs of diabetes begin at least 8 years before diagnosis and grow at an accelerating rate as diagnosis approaches and immediately after diagnosis. These incremental costs span the full range of medical services. Furthermore, the majority of these costs are for conditions not normally associated with diabetes or its complications. Type 2 diabetes is typically asymptomatic early in its course. Consequently, diabetes may exist and its complications may occur before diabetes is recognized (1). Type 2 diabetes also arises within a larger matrix of risk factors for cardiovascular and other diseases, including hypertension, dyslipidemia, and obesity. Some people eventually found to have diabetes will experience ill health and undergo therapy to control risk factors before the recognition of their diabetes. Diabetes Care 23: , 2000 From the Kaiser Permanente Center for Health Research, Portland, Oregon. Address correspondence and reprint requests to Gregory A. Nichols, PhD, Center for Health Research, 3800 N. Interstate Ave., Portland, OR greg.nichols@kp.org. Received for publication 14 March 2000 and accepted in revised form 18 July Abbreviations: CHR, Kaiser Permanente Center for Health Research; HMO, health maintenance organization; KPNW, Kaiser Permanente Northwest Division; NWP, Northwest Permanente Medical Group. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. Many authors have published point estimates of the annual cost of diabetes (2 13). We recently described the time pattern of incremental costs over the first 8 years after diagnosis in a population with known dates of recognition of type 2 diabetes (14). No studies have yet examined the time pattern of costs leading up to diagnosis. Our earlier study indicated that the first year after diagnosis was more expensive than any of the next 5 years. In all 8 years after diagnosis, however, incremental costs were considerably higher for type 2 diabetic patients than for otherwise similar nondiabetic patients. Do these higher incremental costs continue a pattern established before diagnosis, or do they arise from postdiagnostic preventive services and complications? To address this question, we analyzed 8 years of data before, and 3 years of data after, the diagnosis of type 2 diabetes in a large stable representative HMO population. RESEARCH DESIGN AND METHODS Research setting The subjects of this study were members of a long-established nonprofit group-model HMO, Kaiser Permanente Northwest Division (KPNW). KPNW provides comprehensive prepaid coverage to 20% of the Portland, Oregon, population (an average of 400,000 people during the period of this study). Subscribers resemble the area population as a whole (15). All members of KPNW have access to the complete range of medically necessary clinical services. The organization maintains electronic databases containing information on inpatient admissions, pharmacy dispenses, outpatient visits, laboratory tests, and outside claims and referrals. All of these databases are linked through the unique health record number that is given to each member at the time of his or her first enrollment in the health plan. Analysis population Subjects were identified with diabetes by the following: 1) purchasing any medications used to treat diabetes from a KPNW pharmacy; 2) making purchases of blood sugar testing supplies from a KPNW pharmacy, with confirmation of the diagnosis by an endocrinologist; 3) enrolling in diabetes education classes or receiving services from medical office diabetes educators; or 4) leaving an acute care hospital with a discharge diagnosis indicating diabetes. At the request of patients or their clinicians, members who do not have diabetes may be removed from the registry after review and approval by an endocrinologist DIABETES CARE, VOLUME 23, NUMBER 11, NOVEMBER 2000
2 Nichols, Glauber, and Brown Table 1 Number of pairs of subjects by cohort and year before diagnosis Years since diagnosis Cohort , , , ,038 1,143 1, ,056 1,157 1,281 1,160 1, ,010 1,088 1,184 1,318 1,171 1,096 1, ,055 1,155 1,228 1,306 1,386 1,534 1,369 1,272 1,206 Total 869 1,718 2,679 3,715 4,842 6,125 7,563 9,521 8,450 7,783 7,250 Data are n. Our analysis population consisted of all registrants who were newly diagnosed with type 2 diabetes between 1 January1988 and 31 December1995. To identify newly diagnosed patients, we selected all registrants who had 12 full months of health plan eligibility before entry into the registry (on average, study participants had 13 years of eligibility before diagnosis). We defined these individuals as incident cases and assumed that their registry entry date was their date of diagnosis. We limited the study population to patients with probable type 2 diabetes by excluding patients diagnosed before 45 years of age if they had purchased insulin sooner than 2 years after diagnosis. For each study subject, we calculated duration of disease, starting from the day of diagnosis and counting backward or forward in 365-day intervals. Therefore, in this report, year 1 refers not to a calendar year but to the first 365 days preceding diagnosis; year 2 refers to the second 365-day period preceding diagnosis, and so on. Year 1 refers to the first 365-day period after diagnosis. Registrants were included in analyses only for a diagnosis year during which they belonged to the HMO for a full 12 months. Thus, if a registrant joined the health plan 2.5 years before diagnosis, we analyzed data from diagnosis years 1 and 2 but not for his or her first half year of membership. Using this method, a person diagnosed in 1995 could contribute up to 8 years of prediagnosis data and up to 3 years of postdiagnosis data, a person diagnosed in 1994 could contribute up to 7 prediagnosis years and 3 postdiagnosis years, and so on, back to patients diagnosed in 1988, who could contribute only 1 year of prediagnosis data (Table 1). Sample sizes are therefore larger for the years closer to diagnosis. For each study subject in each diagnosis year, we selected a KPNW member without any evidence of diabetes to serve as a control subject. Control subjects were individually matched with study subjects on year of birth, sex, and duration of health plan membership. The matching algorithm assured random assignment within these strata. Utilization data and costs For this report, we retrieved the electronic utilization records for the following: 1) acute hospital admissions to KPNW and non- KPNW hospitals; 2) ambulatory visits to primary care, specialty care, and emergency clinicians; 3) pharmaceuticals and supplies dispensed by KPNW outpatient pharmacies; and 4) ambulatory services provided by non-kpnw individuals and institutions. We did not attempt to ascertain the use of medical services for which the health plan did not pay. We excluded from this report all costs that occurred on the day of diagnosis as well as the costs of hospitalizations during which diabetes was diagnosed. We recently described our determination of unit costs in detail (16). The Kaiser Permanente Center for Health Research (CHR) has developed a system for assigning costs to inpatient services provided in hospitals owned by KPNW based on the Kaiser Permanente s annual Medicare Cost Report (17). For outpatient visits to KPNW clinicians, we used cost coefficients obtained by an internal 1993 study that estimated aggregate visit costs based on salaries by specialty, clinician type (MD, physician assistant, or nurse practitioner), minutes-per-visit by specialty, overhead costs per specialty, and per-visit cost of laboratory services per specialty. To calculate visit costs, we multiplied the relevant coefficient by the total number of visits per specialty department and provider type. This approach somewhat underestimates ambulatory visit costs for diabetic patients, who tend to require more physician time per visit and more laboratory testing than the average patient. Of inpatient and outpatient costs, 30% were for services purchased by the Northwest Permanente Medical Group (NWP) from community providers. We based the cost of these services on the amount Kaiser Permanente actually paid to vendors and combined these costs with the costs of internally produced care. We were unable to assess costs not authorized or paid by NWP (out-of-plan costs). We report costs of drugs and related supplies at their approximate local retail cost at the time of purchase, adjusted to 1998 prices using the pharmaceutical component of the U.S. Medical Price Index (18). Drug cost data are continuously maintained and updated in the KPNW pharmacy-dispensing database for each dosage and the form of each compound. All inpatient and outpatient costs are also reported in 1998 dollars, using cost coefficients derived from 1993 cost data, adjusted for inflation using the U.S. Medical Price Index (18). Our economic perspective was that of the medical insurer; we ignored costs other than those incurred as the result of covered medical services utilization. To calculate net incremental costs for patients who would receive a diabetes diagnosis in the future, we subtracted the costs experienced by matched control patients from the costs experienced by patients who in the future would be diagnosed with type 2 diabetes: thus, costs of type 2 diabetic patients minus costs of nondiabetic patients equals incremental costs of patients with types 2 dia- DIABETES CARE, VOLUME 23, NUMBER 11, NOVEMBER
3 8 Years of costs before diabetes diagnosis Table 2 Annual cost per person, by type and year before diagnosis (U.S. dollars 1998) Inpatient costs Outpatient costs Year Total Incremental Control Total Incremental Control 8 $1,164 ± 186 $9* ± 280 $1,173 ± 205 $1,131 ± 56 $324 ± 66 $807 ± 37 7 $1,735 ± 226 $751 ± 246 $984 ± 104 $1,146 ± 40 $339 ± 49 $807 ± 28 6 $1,330 ± 101 $124* ± 155 $1,206 ± 122 $1,090 ± 29 $277 ± 34 $813 ± 20 5 $1,738 ± 104 $206* ± 154 $1,532 ± 114 $1,202 ± 26 $355 ± 31 $847 ± 18 4 $1,901 ± 113 $438 ± 160 $1,463 ± 116 $1,21 ± 22 $317 ± 29 $902 ± 20 3 $2,177 ± 115 $755 ± 142 $1,422 ± 83 $1,308 ± 22 $403 ± 27 $905 ± 16 2 $2,330 ± 101 $849 ± 121 $1,481 ± 69 $1,378 ± 20 $451 ± 24 $927 ± 14 1 $3,572 ± 128 $1,997 ± 143 $1,575 ± 65 $1,604 ± 22 $652 ± 25 $952 ± 14 Total $15,947 $5,111 $10,836 $10,078 $3,118 $6,960 Average $1,993 $639 $1,355 $1,260 $390 $870 SD $747 $636 $209 $168 $119 $58 Pharmacy costs Total costs 8 $375 ± 35 $156 ± 38 $219 ± 15 $2,670 ± 227 $471* ± 321 $2,199 ± $385 ± 34 $170 ± 35 $215 ± 10 $3,266 ± 245 $1,260 ± 270 $2,006 ± $391 ± 21 $155 ± 22 $236 ± 8 $2,811 ± 120 $556 ± 175 $2,255 ± $403 ± 13 $150 ± 14 $253 ± 8 $3,343 ± 120 $711 ± 171 $2,632 ± $430 ± 16 $151 ± 17 $279 ± 8 $3,550 ± 125 $906 ± 175 $2,644 ± $472 ± 16 $184 ± 18 $288 ± 7 $3,957 ± 127 $1,342 ± 156 $2,615 ± 92 2 $511 ± 15 $203 ± 16 $308 ± 6 $4,21 ± 114 $1,503 ± 136 $2,716 ± 77 1 $568 ± 14 $245 ± 15 $323 ± 6 $5,744 ± 141 $2,894 ± 157 $2,850 ± 73 Total $3,535 $1,414 $2,121 $29,560 $9,643 $19,917 Average $442 $177 $265 $3,695 $1,205 $2,490 SD $69 $33 $41 $979 $780 $296 Data are means ± SEM unless otherwise indicated. *Incremental costs are not statistically significant from zero, P betes. This case-control method allowed us to estimate all the incremental costs of care, not just the costs known to be related to diabetes or its predictors, and to eliminate costs that would have occurred in the absence of future diabetes. It also provided a further control against secular changes in processes of care, prices, and productivity. RESULTS Our study population averaged 60.1 years of age in the year before diagnosis. The group providing data for the eighth prediagnostic year averaged 54.8 years of age at the beginning of their eighth prediagnosis year. In year 1, 47.2% of the cohort were women compared with 50.6% in year 8. For at least 7 years before the diagnosis of diabetes, the total direct medical care costs incurred by patients who were destined to receive the diagnosis of type 2 diabetes significantly exceeded costs for age-, sex-, and eligibility-matched patients without a future diabetes diagnosis. Over the 8-year prediagnosis period, incremental costs averaged $1,205 (± $780) per person per year in 1998 dollars (Table 2). Incremental costs accelerated in the last 3 years before diagnosis. In the final year before diagnosis, incremental costs were nearly double those of the previous year. Control costs grew much more gradually during the study period. Therefore, year-to-year changes in the total costs of patients who were to be diagnosed with diabetes, which more than doubled between years 8 and 1, were mostly driven by the incremental portion of these costs. Inpatient costs accounted for the majority (53%) of the total incremental costs over the prediagnosis years but showed more year-to-year variation than outpatient and pharmaceutical costs. However, for all 8 years before diagnosis, annual incremental outpatient and pharmacy costs were significantly greater for patients who were to receive a diabetes diagnosis. Incremental outpatient costs doubled over the prediagnosis study period, and incremental pharmacy costs grew 57% (from $156 to $245/year). Outpatient costs for patients who would receive a diabetes diagnosis grew gradually over years 8 through 2, but jumped 16%, from $1,378 to $1,604/person in the year just before diagnosis. In the control group, outpatient costs remained relatively flat over the entire 8 years, growing by a total of just 18%. The most costly single class of drugs was antihypertensive agents, with an incremental increase of $48/person per year (Table 3). Together with the other major classes used in cardiovascular treatment and prevention antihyperlipidemics ($10/person per year, incremental) and other cardiovascular drugs ($20/person per year, incremental) antihypertensive costs grew steadily during the study period. However, all other incremental drug costs (costs for drugs other than those used to treat hypertension, hyperlipidemia, and cardiovascular disease) accounted for more incremental expenditures than any other class ($896/person per year; 54% of all incremental drug costs). In Fig. 1, total incremental costs for the 5 years preceding diagnosis are displayed in sequence with costs during the first 3 years after diagnosis. Incremental costs in the year immediately after diabetes diagnosis (year 1) were 41% higher than costs in either the year before or the year after that first postdiagnosis year. Incremental costs doubled in 1656 DIABETES CARE, VOLUME 23, NUMBER 11, NOVEMBER 2000
4 Nichols, Glauber, and Brown Table 3 Annual pharmacy costs per person by drug type and year before diagnosis (U.S. dollars 1998) Antihyperlipidemics costs Antihypertensives costs Year Total Incremental Control Total Incremental Control 8 $17 ± 4 $9 ± 5 $8 ± 3 $85 ± 7 $40 ± 9 $45 ± 5 7 $16 ± 3 $9 ± 3 $7 ± 2 $87 ± 5 $44 ± 6 $43 ± 3 6 $20 ± 2 $10 ± 3 $10 ± 2 $91 ± 4 $46 ± 5 $45 ± 3 5 $21 ± 2 $10 ± 3 $11 ± 2 $97 ± 3 $52 ± 4 $45 ± 2 4 $23 ± 2 $8 ± 3 $15 ± 2 $97 ± 3 $48 ± 3 $49 ± 2 3 $28 ± 2 $11 ± 3 $17 ± 2 $100 ± 2 $49 ± 3 $51 ± 2 2 $31 ± 2 $12 ± 2 $19 ± 1 $103 ± 2 $52 ± 3 $51 ± 2 1 $33 ± 2 $14 ± 2 $19 ± 1 $106 ± 2 $54 ± 2 $52 ± 1 Total $189 $83 $106 $766 $385 $381 Average $24 $10 $13 $96 $48 $48 SD $6 $2 $5 $7 $5 $4 Other cardiovascular costs All other costs Year Total Incremental Control Total Incremental Control 8 $34 ± 5 $17 ± 7 $17 ± 5 $238 ± 32 $89 ± 35 $149 ± 13 7 $40 ± 4 $19 ± 5 $21 ± 3 $243 ± 33 $100 ± 34 $143 ± 8 6 $38 ± 3 $15 ± 4 $23 ± 3 $242 ± 20 $84 ± 20 $158 ± 6 5 $43 ± 3 $16 ± 4 $27 ± 2 $241 ± 11 $71 ± 12 $170 ± 6 4 $46 ± 2 $16 ± 3 $30 ± 2 $261 ± 14 $75 ± 16 $186 ± 7 3 $54 ± 2 $22 ± 3 $32 ± 2 $288 ± 15 $99 ± 16 $189 ± 5 2 $59 ± 2 $25 ± 3 $34 ± 2 $315 ± 14 $11 ± 15 $205 ± 5 1 $63 ± 2 $31 ± 2 $32 ± 2 $358 ± 13 $138 ± 13 $220 ± 5 Total $377 $161 $216 $2,186 $766 $1,420 Average $47 $20 $27 $273 $96 $178 SD $10 $6 $6 $44 $22 $27 Data are means ± SEM. All incremental costs are statistically significant from zero, P Figure 1 Annual incremental and total health care costs per person with type 2 diabetes 5 years before and 3 years after recognition. DIABETES CARE, VOLUME 23, NUMBER 11, NOVEMBER
5 8 Years of costs before diabetes diagnosis the year just before recognition of diabetes, after rising relatively slowly and steadily over 7 of the 8 years preceding recognition. In the year immediately after diagnosis, incremental costs were nearly triple what they had been just 2 years earlier. CONCLUSIONS The challenge in estimating disease-specific incremental costs is to identify the net costs that would not have been incurred had the disease not been present or had the diagnosis not been made. In this article, we estimated net incremental costs of care for 8 years before a diagnosis of type 2 diabetes by subtracting the costs incurred by matched control subjects from the costs of patients who would later be diagnosed with type 2 diabetes. This case-control method, developed by us (19) and also used by Selby et al. (12), is particularly useful in diabetes because much of the excess use caused by diabetes is not explicitly recognized as such in medical and billing records. Because the period of study in this report preceded diagnosis, none of the excess use was formally recognized as being associated with diabetes at the time that it occurred. Thus, the case-control approach may be the only suitable method for the identification of costs before diagnosis. The case-control method also ensures that cases and control subjects are equally exposed to changes in exogenous factors (e.g., as input prices, practice style, utilization controls, surveillance practices). During the 8 years before diagnosis of diabetes, our study shows that patients destined to have diabetes consume significantly more medical care resources than control subjects. Expenditures to prevent cardiovascular disease prominently contributed to health care costs in the years leading up to the recognition of type 2 diabetes. Pharmaceuticals used to treat hypertension, hyperlipidemia, and other cardiovascular risk factors accounted for nearly half (46%) of the overall incremental pharmacy costs that were associated with a future diagnosis of diabetes. However, hospital discharges with a primary diagnosis of cardiovascular disease accounted for only 11% of total diabetesassociated hospital costs (data not shown). We have previously reported that diabetic patients experience significantly increased use of most classes of medications, not just those used to treat diabetes and its microvascular and macrovascular complications (14,19). This pattern describes the prediagnosis period as well, when the majority of drug costs were for noncardiovascular and, of course, non glycemia-related agents. Even more dramatically, 78% of the incremental inpatient costs occurred during admissions caused by conditions seemingly unrelated to diabetes or its complications. These findings tend to rule out unrecognized uncontrolled diabetes as a major explanation for increased costs before diagnosis. One possible explanation for higher incremental costs across-the-board is obesity. A recent study in this setting determined that BMI was an important predictor of future medical care costs in a cohort without a history of coronary heart disease, stroke, or cancer (20). This finding persisted when subjects with evidence of diabetes or hypertension were removed from the analyses. Although we lacked data on obesity in the current study, the well-established association between obesity and diabetes suggests that obesity may at least partially explain the increased costs in patients with prediabetes. Another explanation consistent with the data is that, in the absence of a formal diabetes screening program, increased contact with the medical care system causes the diagnosis of diabetes. Figure 1 illustrates how medical resource use grows rapidly just before diagnosis and falls off afterward. Most of this growth and most of the decrease is attributable to inpatient care, although the actual diagnosis of diabetes rarely occurred during an admission in our data. Moreover, the postdiagnosis decrease would haver been greater if not for the postdiagnostic appearance of drugs, supplies, and visits for the treatment of hyperglycemia (data not shown). Both drug costs and visits costs doubled between years 1 and 1. Increased exposure to medical care could cause diabetes through a variety of mechanisms. Increased contact with health professionals multiplies the opportunities for diabetes to be considered and diagnostic tests to be performed. In addition, however, serious medical conditions create physiological changes that may trigger metabolic decompensation in susceptible patients. Major illness episodes also create psychological stress and precipitate depression. Our data support the hypothesis that diabetes is often induced by deteriorating health and increased contact with the medical care system. More research is needed to better understand the circumstances surrounding the diagnosis of type 2 diabetes. At least 8 years before their diagnosis, patients with type 2 diabetes begin incurring greater health care costs than similar patients without diabetes. These costs rise dramatically once diabetes is about to be recognized. An important topic for further research will be to examine whether this spike in costs is the currently unrecognized physiological result of diabetes and its complications or the result of ill health and the psychological stress and medical attention that accompany it. References 1. Harris MI, Klein R, Welborn TA, Knuman MW: Onset of NIDDM occurs at least 4 7 years before clinical diagnosis. Diabetes Care 15: , Roesler J, Walseth J, Bishop D: The Direct and Indirect Costs of Diabetes in Minnesota in Minneapolis, MN, Minnesota Dept. of Health, Scott RS, Brown LJ, Clifford P: Use of health services by diabetic persons. II. Hospital admissions. Diabetes Care 8:43 47, Weinberger M, Cowper PA, Kirkman MS, Vinicor F: Economic impact of diabetes mellitus in the elderly. Clin Geriatr Med 6: , Krosnick A: Economic impact of type II diabetes mellitus. Primary Care 15: , Huse DM, Oster G, Killen AR, Lacy MJ, Colditz GA: The economic cost of noninsulin dependent diabetes mellitus. JAMA 262: , Taylor AK: Medical expenditures and insurance coverage for people with diabetes: estimates from the National Medical Care Expenditure Survey. Diabetes Care 10:87 91, Rendell M, Kimmel D, Bamisedun O, O Donnell ET, Fulmer J: The health care status of the diabetic population as reflected by physician claims to a major insurer. Arch Intern Med 153: , Rendell M, Ross DA, Lassek WD, Kernek S, Williams J, Smith C, Willingmyre L, Yamamoto L: A pharmaceutical profile of diabetic patients. J Chronic Dis 36: , Center for Economic Studies in Medicine: Direct and Indirect Cost of Diabetes in the United States in Alexandria, VA, American Diabetes Association, Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus, J Clin Endocrinol Metab 78:809A 809F, Selby JV, Ray GT, Zhang D, Colby CJ: Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 20: , DIABETES CARE, VOLUME 23, NUMBER 11, NOVEMBER 2000
6 Nichols, Glauber, and Brown 13. American Diabetes Association: Economic consequences of diabetes mellitus in the U.S. in Diabetes Care 21: , Brown JB, Nichols GA, Glauber HS, Bakst AW: Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 22: , Greenlick M, Freeborn D, Pope C: Health Care Research in an HMO: Two Decades of Discovery. Baltimore, MD, Johns Hopkins University Press, Brown JB, Pedula KL, Bakst AW: The progressive cost of complications in type 2 diabetes. Arch Intern Med 159: , Hornbrook MC, Goodman MJ: Adjusting health benefit contributions to reflect risk. In Advances in Health Economics and Health Services Research. Hornbrook MC, Ed. Greenwich, CT, JAI Press, 1991, p U.S. Bureau of Labor Statistics: Consumer Price Index for All Items and for Medical Care: CPI Detailed Report, Filename: SD-013, Glauber HS, Brown JB: Use of HMO pharmacy databases to study the quality of care and resource use in diabetes mellitus. Diabetes Care 15: , Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G: Body mass index and future health-care costs: a retrospective cohort study. Obes Res. In press DIABETES CARE, VOLUME 23, NUMBER 11, NOVEMBER
The Impact of Cardiovascular Disease on Medical Care Costs in Subjects With and Without Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E The Impact of Cardiovascular Disease on Medical Care Costs in Subjects With and Without Type 2 Diabetes GREGORY A. NICHOLS,
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationASSOCIATION OF ASTHMA CONTROL WITH HEALTH CARE UTILIZATION A PROSPECTIVE EVALUATION
Online Supplement for: ASSOCIATION OF ASTHMA CONTROL WITH HEALTH CARE UTILIZATION A PROSPECTIVE EVALUATION METHODS Population The Northwest Region of Kaiser Permanente (KPNW) is a large, federally qualified,
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationDiabetes Care 26: , 2003
Epidemiology/Health Services/Pyschosocial Research O R I G I N A L A R T I C L E The Direct Medical Cost of Type 2 Diabetes MICHAEL BRANDLE, MD 1 HONGHONG ZHOU, MS 2 BARBARA R.K. SMITH, MHSA 1 DEANNA MARRIOTT,
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 6: Medicare Expenditures for Persons With CKD Medicare spending for patients with CKD aged 65 and older exceeded $50 billion in 2013, representing 20% of all
More informationONE of every seven dollars spent on health care in the
0021-972X/98/$03.00/0 Vol. 83, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Clinical and Economic Impact of Implementing a Comprehensive
More informationChronicity and Aging: The Geriatric Imperative
Chronicity and Aging: The Geriatric Imperative Steven L. Phillips, MD Medical Director Sanford Center for Aging Professor, Clinical Internal Medicine University of Nevada, Reno School of Medicine dhs.unr.edu/aging
More informationComparative Analysis of Individuals With and Without Chiropractic Coverage Patient Characteristics, Utilization, and Costs
Comparative Analysis of Individuals With and Without Chiropractic Coverage Patient Characteristics, Utilization, and Costs 1 Archives of Internal Medicine. October 11, 2004;164:1985-1992 Antonio P. Legorreta,
More informationValue of Hospice Benefit to Medicaid Programs
One Pennsylvania Plaza, 38 th Floor New York, NY 10119 Tel 212-279-7166 Fax 212-629-5657 www.milliman.com Value of Hospice Benefit May 2, 2003 Milliman USA, Inc. New York, NY Kate Fitch, RN, MEd, MA Bruce
More informationThe clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes
The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes September, 2017 White paper Life Sciences IHS Markit Introduction Diabetes is one of the most prevalent
More informationAlthough the prevalence and incidence of type 2 diabetes mellitus
n clinical n Validating the Framingham Offspring Study Equations for Predicting Incident Diabetes Mellitus Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP Background: Investigators from the Framingham
More informationADR 2014 Data Validations
Grantee Report Validation Checks Q. #2 Poverty Level is required Q. #3 Clinical Eligibility is required Q. #4 Drug Pricing program is required Q. #5 Funding Total (a through h) must be greater than zero
More informationCOSTS OF DIABETES IN DEVELOPING COUNTRIES
COSTS OF DIABETES IN DEVELOPING COUNTRIES Jonathan Betz Brown, MPP, PhD Chair, International Diabetes Federation Task Force on Diabetes Health Economics Senior Investigator, Kaiser Permanente Center for
More informationDIABETES AND THE AT-RISK LOWER LIMB:
DIABETES AND THE AT-RISK LOWER LIMB: Shawn M. Cazzell Disclosure of Commercial Support: Dr. Shawn Cazzell reports the following financial relationships: Speakers Bureau: Organogenesis Grants/Research Support:
More informationAttributing Inpatient Medicare Costs to Diabetes Among the Texas Elderly
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Attributing Inpatient Medicare Costs to Diabetes Among the Texas Elderly ROY R. MCCANDLESS, DRPH OBJECTIVE This study compares
More informationMedicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment
American Hospital association December 2012 TrendWatch Are Medicare Patients Getting Sicker? Today, Medicare covers more than 48 million people, and that number is growing rapidly baby boomers are reaching
More informationSupplementary Online Content
Supplementary Online Content Friedberg MW, Rosenthal MB, Werner RM, Volpp KG, Schneider EC. Effects of a medical home and shared savings intervention on quality and utilization of care. Published online
More informationHypertension Update 2014:
GSHTP Webinar Hypertension Update 2014: The Kaiser Permanente Northern California Experience Presented by: Marc Jaffe, MD Associate Clinical Professor of Medicine, UCSF Kaiser Permanente Northern California
More informationhad non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;
Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries Weiss J P, Saynina O, McDonald K M, McClellan M
More informationObesity: Trends, Impact, Complexity
Obesity: Trends, Impact, Complexity Ross A. Hammond, Ph.D. Director, Center on Social Dynamics & Policy Senior Fellow, Economic Studies Program The Brookings Institution Attorneys General Education Program
More informationCoordinated End-of-Life Care Improves Wellbeing and Produces Cost Savings POLICY BRIEF: Lydia Ogden, MA, MPP and Kenneth Thorpe, PhD
CENTER FOR ENTITLEMENT REFORM POLICY BRIEF: Coordinated End-of-Life Care Improves Wellbeing and Produces Cost Savings Lydia Ogden, MA, MPP and Kenneth Thorpe, PhD SEPTEMBER 2009 Most Americans are seriously,
More informationThe Florida Diabetes Master Clinician Program: Facilitating Increased Quality and Significant Cost Savings for Diabetic Patients
The Florida Diabetes Master Clinician Program: Facilitating Increased Quality and Significant Cost Savings for Diabetic Patients Edward Shahady, MD, ABCL, ABFM, FAAFP Up to 10% of Americans > 20 years
More informationChapter 5: Cost of Chiropractic Compared to Family Physician
ICA Best Practices & Practice Guidelines 47 Chapter 5: Cost of Chiropractic Compared to Family Physician Introduction Here we explore the cost of chiropractic care versus the cost of care provided by medical
More informationThe cost burden of diabetes mellitus: the evidence from Germany the CoDiM Study
Diabetologia (2006) 49: 1498 1504 DOI 10.1007/s00125-006-0277-5 ARTICLE I. Köster. L. von Ferber. P. Ihle. I. Schubert. H. Hauner The cost burden of diabetes mellitus: the evidence from Germany the CoDiM
More informationChronic Diseases in the Elderly. Steven L. Phillips, MD Medical Director Sanford Center for Aging University of Nevada, Reno
Chronic Diseases in the Elderly Steven L. Phillips, MD Medical Director Sanford Center for Aging University of Nevada, Reno A Partnership of Project ECHO, Sanford Center for Aging, and the Nevada Geriatric
More informationBody Mass Index Measurement and Obesity Prevalence in Ten U.S. Health Plans
CM&R Rapid Release. Published online ahead of print August 3, 2010 as Original Research Body Mass Index Measurement and Obesity Prevalence in Ten U.S. Health Plans David E. Arterburn, MD, MPH; Gwen L.
More informationIn the United States, caring for patients with diabetes
Diabetes and Clinical Outcomes: The Harbor City, California Kaiser Permanente Diabetes System Edward S. Domurat, MD Abstract Objective: To investigate diabetes clinical outcomes in a large patient population
More informationObesity and Medical Nutrition Therapy. Deborah B. Munchmeyer Program Manager, SCDHHS Coverage and Benefit Design March 10, 2018
Obesity and Medical Nutrition Therapy Deborah B. Munchmeyer Program Manager, SCDHHS Coverage and Benefit Design March 10, 2018 Obesity What, Why and How? Source: American Association of Clinical Endocrinologists
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationHealth Care Use and Costs in the Decade After Identification of Type 1 and Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Health Care Use and Costs in the Decade After Identification of and Diabetes A population-based study JEFFREY A. JOHNSON,
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationDiabetes Hospitalization in Minnesota
Diabetes Hospitalization in Minnesota 2006-2014 Diabetes Hospitalization in Minnesota, 2006-2014 Minnesota Department of Health Diabetes Unit PO Box 64882, St. Paul, MN 55164-0882 651-201-4634 Renee.Kidney@state.mn.us
More informationBridges to Excellence: Recognizing High-Quality Care. Meredith B. Rosenthal, Ph.D. October 19, 2008
Bridges to Excellence: Recognizing High-Quality Care Meredith B. Rosenthal, Ph.D. October 19, 2008 1 Acknowledgements My coauthors: Francois DeBrantes, Anna Sinaiko, Matt Frankel, Russell Robbins, Sara
More information8/12/2016. Outline. New CPT Code for Pre-Diabetes Education. Medicare Proposed Coverage for DPP. Medicare Proposed Coverage for DPP cont.
New CPT Code for Pre-Diabetes Education 0403T: Preventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals
More informationmedicaid and the The Role of Medicaid for People with Diabetes
on medicaid and the uninsured The Role of for People with Diabetes November 2012 Introduction Diabetes is one of the most prevalent chronic conditions and a leading cause of death in the United States.
More informationLOUISIANA MEDICAID PROGRAM ISSUED: 02/01/12 REPLACED: 02/01/94 CHAPTER 5: PROFESSIONAL SERVICES SECTION 5.1: COVERED SERVICES PAGE(S) 6
Diabetes Education Management Training Diabetes self management training (DSMT) is a collaborative process through which recipients with diabetes gain knowledge and skills needed to modify behavior and
More informationManaging Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More informationDiabetes Care 26: , 2003
Epidemiology/Health Services/Pyschosocial Research O R I G I N A L A R T I C L E Complications in Young Adults With Early-Onset Type 2 Diabetes Losing the relative protection of youth TERESA A. HILLIER,
More informationCounty of Sacramento. Review of Population Health through Kaiser Permanente Data
County of Sacramento Review of Population Health through Kaiser Permanente Data Dr. Diane Dailey, M.D., Chief of Business Health Engagement Eileen Peterson, MPH, RD, TPMG Business Health Consultant, Public
More informationACO #44 Use of Imaging Studies for Low Back Pain
Measure Information Form (MIF) DATA SOURCE Medicare Claims Medicare beneficiary enrollment data MEASURE SET ID ACO #44 VERSION NUMBER AND EFFECTIVE DATE Version 1, effective 01/01/18 CMS APPROVAL DATE
More informationThe Value of Providing Collaborative Care Models For Treating Employees with Depression
The Value of Providing Collaborative Care Models For Treating Employees with Depression Summary Depression is one of the costliest health issues for employers because of its high prevalence and co-morbidity
More informationMerit-based Incentive Payment System (MIPS): Cost Measure Field Test Reports Fact Sheet
Merit-based Incentive Payment System (MIPS): Cost Measure Field Test Reports Fact Sheet The Quality Payment Program The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) established the Quality
More informationPharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy. Pharmacists Role 1
Pharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy Pharmacists Role 1 Promotion of health improvement, wellness, and disease prevention in cooperation
More informationJae Jin An, Ph.D. Michael B. Nichol, Ph.D.
IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS Jae Jin An, Ph.D. Michael B. Nichol, Ph.D.
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationType of intervention Secondary prevention. Economic study type Cost-effectiveness analysis.
Improved outcomes in indigent patients with ketosis-prone diabetes: effect of a dedicated diabetes treatment unit Maldonado M R, D'Amico S, Rodriguez L, Iyer D, Balasubramanyam A Record Status This is
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More information$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2)
Benefit Summary Outpatient Prescription Drug Illinois 5/50/100/250 Plan 455 Your Co-payment and/or Co-insurance is determined by the tier to which the Prescription Drug List (PDL) Management Committee
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set
More informationLack of documentation on overweight & obese status in patients admitted to the coronary care unit: Results from the CCU study
Lack of documentation on overweight & obese status in patients admitted to the coronary care unit: Results from the CCU study Meriam F. Caboral,, RN, MSN, NP-C Clinical Coordinator Heart Failure Components
More informationEffectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
More informationA Model for Comparing Unnecessary Costs Associated with Various Prescription Fill-Quantity Policies: Illustration Using VA Data
RESEARCH A Model for Comparing Unnecessary Costs Associated with Various Prescription Fill-Quantity Policies: Illustration Using VA Data OBJECTIVE: To describe a model for analyzing the unnecessary costs
More informationAnesthesia Reimbursement
This drafted policy is open for a two-week public comment period. This box is not part of the drafted policy language itself, and is intended for use only during the comment period as a means to provide
More informationArchimedes, Medicare, and ARCHeS
Archimedes, Medicare, and ARCHeS David M Eddy MD PhD Archimedes, Inc www.archimedesmodel.com National Health Policy Forum Washington, DC June 8, 2007 Outline 1. The Archimedes Model Why we built it What
More informationREVIEW AND FREQUENTLY ASKED QUESTIONS (FAQ) 8/5/2015. Outline. Navigating the DSMT Reimbursement Maze in Todays Changing Environment
Patty Telgener RN, MBA, CPC VP of Reimbursement Emerson Consultants Navigating the DSMT Reimbursement Maze in Todays Changing Environment Patty Telgener, RN, MBA, CPC VP of Reimbursement Emerson Consultants
More informationWebinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve.
Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve April 22, 2015 Qualis Health A leading national population health management organization
More informationSupplementary Online Content
Supplementary Online Content Arrieto A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private
More informationAN INDIRECT EVALUATION OF THE NATIONAL PROGRAM OF DIABETES MELLITUS STUDY CASE OF ROMANIA
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2013 vol. 117, no. 2 PREVENTIVE MEDICINE - LABORATORY ORIGINAL PAPERS AN INDIRECT EVALUATION OF THE NATIONAL PROGRAM OF DIABETES MELLITUS STUDY CASE OF ROMANIA Maria
More informationSetting The setting was community. The economic study was carried out in the USA.
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children Lieu T A, Ray G T, Black S R, Butler J C, Klein J O, Breiman R F, Miller M A, Shinefield H R Record
More informationBC Methadone Maintenance System: Performance Measures 2011/2012 Appendix A: Report Figures and Data
BC Methadone Maintenance System: Performance Measures 2011/2012 Pharmaceutical Services Division & Population and Public Health Division British Columbia Ministry of Health February 2013 You may download
More informationPerformance Measure Name: TOB-3 Tobacco Use Treatment Provided or Offered at Discharge TOB-3a Tobacco Use Treatment at Discharge
Measure Information Form Collected For: The Joint Commission Only CMS Informational Only Measure Set: Tobacco Treatment (TOB) Set Measure ID #: Last Updated: New Measure Version 4.0 Performance Measure
More informationDiabetes Care 34: , 2011
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Medical Care Costs Associated With Progression of Diabetic Nephropathy GREGORY A. NICHOLS, PHD 1 SUMA VUPPUTURI, PHD 2 HELEN LAU, MS
More informationA nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD
The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei
More informationDepression and Anxiety Relative Risks in Women Newly Diagnosed with Vulvovaginal Atrophy and Dyspareunia
Depression and Anxiety Relative Risks in Women Newly Diagnosed with Vulvovaginal Atrophy and Dyspareunia Moyneur, Erick MA 1, Dea, Katherine MSc 1, Derogatis, Len PhD 2, Labrie, Fernand MD, PhD 3 1 StatLog
More informationDiabetes in Manitoba 1989 to 2006 R E P O R T O F D I A B E T E S S U R V E I L L A N C E
Diabetes in Manitoba 1989 to 2006 R E P O R T O F D I A B E T E S S U R V E I L L A N C E May 2009 Key Results Diabetes Prevalence Manitoba has experienced a considerable growth in the number of people
More informationThis slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both
This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both direct and indirect and the projected burden of diabetes,
More informationProjection of Diabetes Burden Through 2050
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Projection of Diabetes Burden Through 2050 Impact of changing demography and disease prevalence in the U.S. JAMES P. BOYLE,
More informationDo OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018
Question: Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018 An examination of health improvements, utilization & cost of care for
More informationUPDATE: Screening and Coverage for Diabetes and Prediabetes. Karin Gillespie, Changing Diabetes Policy, Novo Nordisk
UPDATE: Screening and Coverage for Diabetes and Prediabetes Karin Gillespie, Changing Diabetes Policy, Novo Nordisk 2 USPSTF Diabetes Screening Guideline New USPSTF Abnormal Blood Glucose and Type 2 Diabetes
More informationModular Program Report
Disclaimer The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also
More informationDefinition. Synonyms 9/23/2010. Trials for which the hypothesis and study design are formulated based on information needed to make a decision
Scott Ramsey, MD, PhD Definition Trials for which the hypothesis and study design are formulated based on information needed to make a decision Synonyms Pragmatic clinical trials Practical clinical trials
More informationPer Capita Health Care Spending on Diabetes:
Issue Brief #10 May 2015 Per Capita Health Care Spending on Diabetes: 2009-2013 Diabetes is a costly chronic condition in the United States, medical costs and productivity loss attributable to diabetes
More informationIssue Brief. Eliminating Adult Dental Benefits in Medi-Cal: An Analysis of Impact. Introduction. Background
Eliminating Adult Dental Benefits in Medi-Cal: An Analysis of Impact Introduction In 2009, California eliminated non-emergency dental services for adults in its Medicaid program, Medi-Cal. The California
More informationHospice and Palliative Care An Essential Component of the Aging Services Network
Hospice and Palliative Care An Essential Component of the Aging Services Network Howard Tuch, MD, MS American Academy of Hospice and Palliative Medicine Physician Advocate, American Academy of Hospice
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None BURDEN OF CORONARY ARTERY DISEASE IN DIABETES IN INDIA Amal Kumar Banerjee MD, DM,FACC,FESC,FACP,FAPSC,FICC President Association of Physicians of India SAARC Cardiac
More informationICD-10CM, HCC and Risk Adjustment Factor
ICD-10CM, HCC and Risk Adjustment Factor Not everyone is aware of what CMs calls the risk adjustment model. It was developed under the Patient Protection and Affordable Care Act (also known as the PACA)
More informationMonthly Campaign Webinar February 21, 2019
Monthly Campaign Webinar February 21, 2019 2 Today s Webinar Together 2 Goal Updates Webinar Reminders AMGA Annual Conference New Campaign Partnership 2019 Million Hearts Hypertension Control Challenge
More informationManaged Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More informationTime Series Analysis for selected clinical indicators from the Quality and Outcomes Framework
Time Series Analysis for selected clinical indicators from the Quality and Outcomes Framework 21-26 Title Document Type Time Series Analysis for selected clinical indicators from the Quality and Outcomes
More informationNever has there been a more
ABattle We Can t Afford tolose The Burden of Overweight and Obesity in Texas: The Costs in Dollars and Lives Never has there been a more critical time to ensure a healthy future for our children. In the
More informationHypertension Screening: Technical Report Prepared for the National Commission on Prevention Priorities
Hypertension Screening: Technical Report Prepared for the National Commission on Prevention Priorities Version 06.1; last updated August 19, 2008 Prepared by Michael V. Maciosek, PhD* Nichol M. Edwards,
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury In 2015, 4.3% of Medicare fee-for-service beneficiaries experienced a hospitalization complicated by Acute Kidney Injury (AKI); this appears to have plateaued since 2011
More informationLIMITED EVIDENCE IS AVAILable
EPIDEMIOLOGY Changes in Incidence of Diabetes Mellitus Related Eye Disease Among US Elderly Persons, -2005 Frank A. Sloan, PhD; Daniel Belsky, BA; David Ruiz Jr, BS; Paul Lee, MD, JD Objectives: To determine
More informationVoluntary Mental Health Treatment Laws for Minors & Length of Inpatient Stay. Tori Lallemont MPH Thesis: Maternal & Child Health June 6, 2007
Voluntary Mental Health Treatment Laws for Minors & Length of Inpatient Stay Tori Lallemont MPH Thesis: Maternal & Child Health June 6, 2007 Introduction 1997: Nearly 300,000 children were admitted to
More informationA COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH:
A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: Amputee Coalition of America Mended Hearts National Federation of the Blind National Kidney Foundation
More informationHealth plans are charged with the difficult balance of
RESEARCH Measuring Economic Impact of Applying Daily Average Consumption Limits Bridget M. Flavin, PharmD; Lynn M. Nishida, RPh; Sean H. Karbowicz, PharmD; Mark E. Renner; and Ruth J. Leonard, PharmD ABSTRACT
More informationIMPACT OF RECENT CHANGES IN DIAGNOSTIC CRITERIA ON THE APPARENT NATURAL HISTORY OF DIABETES MELLITUS
AMERICAN JOURNAL OF EPIDIMIOLOCY Copyright 1983 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 117, No. 6 Fruited in U.SA. IMPACT OF RECENT CHANGES IN DIAGNOSTIC
More informationCost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY
Cost of Diabetes Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Christopher Stanley, MD, MBA American Diabetes Association Colorado Advocacy Chair Vice President of Population Health
More informationA comparison of diabetic complications and health care utilization in diabetic patients with and without
John A. Dufton, DC, MD, Wilson W. Li, BSc (Pharm), MD, Mieke Koehoorn, PhD A comparison of diabetic complications and health care utilization in diabetic patients with and without comorbid A Canadian cross-sectional
More informationPerformance Measure Name: Tobacco Use: Assessing Status after Discharge
Measure Information Form Collected For: The Joint Commission Only CMS Informational Only Measure Set: Tobacco Treatment (TO) Set Measure ID #: Last Updated: New Measure Version 4.0 Performance Measure
More informationBilling and Coding Guidelines for Allergy Immunotherapy
Billing and Coding Guidelines for Allergy Immunotherapy LCD Database ID L36408 Billing Guidelines Evaluation and management (E/M) codes reported with allergy immunotherapy are appropriate only if a significant,
More informationPerformance Analysis:
Performance Analysis: Healthcare Utilization of CCNC- Population 2007-2010 Prepared by Treo Solutions JUNE 2012 Table of Contents SECTION ONE: EXECUTIVE SUMMARY 4-5 SECTION TWO: REPORT DETAILS 6 Inpatient
More informationThe Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD
The Link Between Acute and Chronic Kidney Disease John Arthur, MD, PhD Conventional Dogma Conventional dogma was that if a patient survived and recovered from AKI, he was unlikely to have long-term sequela.
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More information